Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03228277
Recruitment Status : Completed
First Posted : July 24, 2017
Last Update Posted : August 28, 2019
Sponsor:
Collaborator:
Hanmi Pharmaceutical Company Limited
Information provided by (Responsible Party):
Kye Young Lee, Konkuk University Medical Center

Brief Summary:
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage fluid.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Drug: Olmutinib Phase 2

Detailed Description:
This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of Olmutinib(Olita®) administered to patients with T790M-positive NSCLC confirmed using DNA extracted from extracellular vesicles in bronchoalveolar lavage fluid as measured by objective response rate (ORR).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid
Actual Study Start Date : July 17, 2017
Actual Primary Completion Date : July 31, 2018
Actual Study Completion Date : July 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Olmutinib
Single arm of Olmutinib, staring dose of 800 mg
Drug: Olmutinib
Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
Other Name: Olita®




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months ]
    defined as the proportion of patients who achieved complete remission(CR) or partial remission(PR) based on RECIST version 1.1


Secondary Outcome Measures :
  1. Disease control rate (DCR) [ Time Frame: Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months ]
    defined as the proportion of patients with a documented CR, PR, and SD during the treatment cycles according to the RECIST version 1.1

  2. Progression-free survival (PFS) [ Time Frame: Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months ]
    defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, aged at least 19 years
  2. Obtained written informed consent
  3. Histologically- or cytologically confirmed diagnosis of unresectable Stage IIIB or IV non-small cell lung cancer.
  4. Confirmation that the tumor harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
  5. Eastern Cooperative Oncology Group performance status of 0 to 2
  6. Prior treatment with at least one line of a single agent EGFR TKI (gefitinib, erlotinib, afatinib) and confirmed progressive disease after treatment with EGFR TKI

    • Regardless of treatment sequence between previous chemotherapy and EGFR TKI
    • Regardless of whether they were administered conventional chemotherapy, if therapy were treated with at least one EGFR TKI
  7. Subjects who will undergo bronchoscopy/ BAL procedures and sufficient amount of BAL fluid is carefully collected for EGFR mutation analysis.
  8. Confirmation that the extracellular vesicles (EV) extracted from bronchoalveolar lavage fluid (BALF) harbour T790M mutation (It can be replaced previous the same result throughout the follow up period before enrollment.)
  9. At least one measurable disease (except brain) at baseline according to RECIST version 1.1
  10. Female subjects must be postmenopausal (for at least one year), or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, have a negative urinary β-hCG pregnancy test at screening.
  11. Male subjects should be willing to use barrier methods which are suitable for sexual partner throughout the study.
  12. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. The subject also must sign and date the consent form before specific procedures or sampling.
  13. Adequate organ function as defined by liver, kidney, and hematologic laboratory testing as below

    • Absolute neutrophil count (ANC) ≥ 1500/mm3, Platelet ≥ 100,000 /mm3 Hemoglobin (Hb) ≥ 9.0g/dL
    • Serum creatinine ≤ upper limit of normal (ULN)
    • AST/ALT/ALP ≤ 3 times ULN, Total bilirubin ≤2.0 mg/dL AST/ALT/ALP ≤ 5 times ULN in patients with metastatic lesions to the liver ALP ≤ 5 times ULN in patients with metastatic lesions to the bone
  14. Expected survival of at least 12 weeks

Exclusion Criteria:

  1. Previous treatment with anticancer therapies, EGFR-TKI, olmutinib (HM61713), or other drugs that target T790M-positive mutant EGFR with sparing of wild-type, Osimertinib (AZD9291), Rociletinib (CO-1686), investigational agent(s) within 30 days prior to the first administration of study drug, radiotherapy
  2. Treatment with a potent cytochrome P450 (CYP) 3A4 inhibitors or inducers
  3. History of any other malignancy EXCEPTIONS are:

    • adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, thyroid cancer
    • other malignancies diagnosed prior to randomisation and treated with no evidence of disease recurrence more than 3 years
  4. Any history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of III or IV, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to enrolment. Increased QTc interval > 450 ms on screening ECG
  5. Any history of presence of interstitial lung disease
  6. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption).
  7. Ongoing active infection with, hepatitis B virus (infection defined as a positive HbsAg and/ or HBV DNA), hepatitis C virus (infection defined as a positive HCV RNA), or human immunodeficiency virus (HIV) Type 1/2 infection at the time of screening.
  8. Known history of hypersensitivity to active or inactive excipients of study drug (olmutinib) or drugs with a similar chemical structure of olmutinib
  9. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  10. Symptomatic or uncontrolled central nervous system (CNS) metastases (Patients are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically and radiologically stable)
  11. Uncontrolled active infectious disease (with the exception of those that are considered to be needed topical antibiotics, however subjects can be enrolled into the study after they complete their treatment)
  12. Unable to attend all the study visits or comply with study procedures
  13. Patients who had received other investigational product within 30 days prior to the first administration of study drug except for gefitinib, erlotinib, or afatinib

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03228277


Locations
Layout table for location information
Korea, Republic of
Konkuk University Medical Center
Seoul, Korea, Republic of, 05030
Sponsors and Collaborators
Konkuk University Medical Center
Hanmi Pharmaceutical Company Limited
Investigators
Layout table for investigator information
Principal Investigator: Kye Young Lee Konkuk University Medical Center
Layout table for additonal information
Responsible Party: Kye Young Lee, Professor, Konkuk University Medical Center
ClinicalTrials.gov Identifier: NCT03228277    
Other Study ID Numbers: KASTT005_BAL_Olita
First Posted: July 24, 2017    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Kye Young Lee, Konkuk University Medical Center:
Extracellular vesicles
Bronchoalveolar lavage fluid
Liquid biopsy
T790M
NSCLC
Exosomes
EGFR mutation testing
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases